SEC Comment Letter 0000000000-24-012643 to Unicycive Therapeutics, Inc. (UNCY) (CIK 0001766140) (UNCY)
Unicycive Therapeutics, Inc. (UNCY) (CIK 0001766140)
Date: Nov. 14, 2024 · CIK: 0001766140 · Accession: 0000000000-24-012643
AI Filing Summary & Sentiment
File numbers found in text: 333-283210
Letter
November 14, 2024 Shalabh Gupta, M.D. Chief Executive Officer Unicycive Therapeutics, Inc. 4300 El Camino Real, Suite 210 Los Altos, CA 94022 Re:Unicycive Therapeutics, Inc. Registration Statement on Form S-3 Filed November 13, 2024 File No. 333-283210 Dear Shalabh Gupta M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jeffrey J. Fessler, Esq.
Show Raw Text
November 14, 2024
Shalabh Gupta, M.D.
Chief Executive Officer
Unicycive Therapeutics, Inc.
4300 El Camino Real, Suite 210
Los Altos, CA 94022
Re:Unicycive Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 13, 2024
File No. 333-283210
Dear Shalabh Gupta M.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jeffrey J. Fessler, Esq.